Entera Bio Ltd.ENTXEarnings & Financial Report
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing oral formulations of biologics and large-molecule therapies traditionally administered via injection. Its core pipeline targets treatments for rare diseases, metabolic disorders, and autoimmune conditions, serving patient populations across global markets.
Revenue
$57.0K
Gross Profit
$9.0K
Operating Profit
$-2.2M
Net Profit
$-2.1M
Gross Margin
15.8%
Operating Margin
-3798.2%
Net Margin
-3763.2%
YoY Growth
N/A
EPS
$0.06
Entera Bio Ltd. Q2 FY2024 Financial Summary
Entera Bio Ltd. reported revenue of $57.0K for Q2 FY2024, with a net profit of $-2.1M (up 7.7% YoY) (-3763.2% margin). Cost of goods sold was $48.0K, operating expenses totaled $2.2M.
Key Financial Metrics
| Total Revenue | $57.0K |
|---|---|
| Net Profit | $-2.1M |
| Gross Margin | 15.8% |
| Operating Margin | -3798.2% |
| Report Period | Q2 FY2024 |
Entera Bio Ltd. Annual Revenue by Year
Entera Bio Ltd. annual revenue history includes year-by-year totals (for example, 2025 revenue was $42.0K).
| Year | Annual Revenue |
|---|---|
| 2025 | $42.0K |
| 2024 | $181.0K |
| 2023 | $0 |
| 2022 | $134.0K |
Entera Bio Ltd. Quarterly Revenue & Net Profit History
Entera Bio Ltd. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-3.0M | N/A |
| Q3 FY2025 | $0 | — | $-3.2M | N/A |
| Q2 FY2025 | $0 | — | $-2.7M | N/A |
| Q1 FY2025 | $42.0K | — | $-2.6M | -6111.9% |
| Q4 FY2024 | $82.0K | — | $-2.4M | -2875.6% |
| Q3 FY2024 | $42.0K | — | $-3.0M | -7192.9% |
| Q2 FY2024 | $57.0K | — | $-2.1M | -3763.2% |
| Q1 FY2024 | $0 | — | $-2.0M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $57000 | $42000 | $82000 | $42000 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.2M | $10.0M | $7.7M | $9.4M | $21.6M | $19.7M | $17.4M | $16.0M |
| Liabilities | $1.4M | $1.5M | $1.3M | $1.3M | $2.2M | $2.4M | $2.2M | $2.9M |
| Equity | $8.9M | $8.5M | $6.5M | $8.1M | $19.4M | $17.3M | $15.2M | $13.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.9M | $-1.3M | $-2.2M | $-1.5M | $-1.4M | $-1.6M | $-2.5M | $-1.8M |